Noerr advises Zyto group on takeover by ArchiMed
Under the leadership of Thorsten Reinhard and Laurenz Tholen, Noerr has advised the shareholders of the Zyto group, which specialises in cancer diagnostics, on the takeover by the MED II Fund of French private equity firm ArchiMed.
With this takeover, ArchiMed, an investor specialising in the healthcare industry, is acquiring a fully integrated developer, manufacturer and distributor of technologically advanced tests and devices for cancer diagnostics. As part of the transaction, ArchiMed is acquiring the three operational entities Zytomed, ZytoVision and 42 Life Sciences. With ArchiMed’s support, the group is anticipated to quickly become a European market leader in diagnostics for personalised cancer therapies. The founders and managing directors of the three companies will hold a significant minority shareholding in the group.
Noerr advised the sellers extensively on structuring and implementing the transaction including their future participation in the group.
Advisors to Zyto group: Noerr Partnerschaftsgesellschaft mbB
Lead: Dr Thorsten Reinhard (Corporate/M&A, Frankfurt), Dr Laurenz Tholen (Private Equity, Berlin)
Dr Carsten Heinz (Munich)
Dr Bärbel Sachs, Dr Johannes Schäffer (both Berlin)
Pascal Schumacher, Henrike von dem Berge (both Berlin)
Dr Stefan Schwab (Berlin), Nathalie Kibler (Hamburg)
Private equityDr Anna Olbrys-Sobieszuk, Alison Heinze (both Berlin)